Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.

Neurology - 1 Jul 2025

Lanman Tyler, Densmore Isabella, Nagpal Seema, Recht Lawrence, McGranahan Tresa

Abstract excerpt

BACKGROUND AND OBJECTIVES: Current treatment guidelines for patients with isocitrate dehydrogenase (IDH)-mutant (IDHm) glioma recommend radiation (XRT) and chemotherapy after surgery in most cases based on studies in which XRT was compared with XRT plus chemotherapy. Although XRT has been shown to improve time to tumor progression, there has never been a controlled study in this population in which adjuvant XRT...

Read the complete abstract on PubMed

Topics

Adult
Aged
Female
Humans
Male
Middle Aged
Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Cohort Studies

Glioma

Isocitrate Dehydrogenase

Mutation

Neoplasm Grading

Radiotherapy, Adjuvant

Retrospective Studies

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40513058
DOI: 10.1212/WNL.0000000000213797
PMCID: PMC12179783

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.PMID 40513058Read ↗

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.Semantic proximity Read ↗

Clinical Characteristics, Treatment Outcomes, And Genetic Alterations of Radiation-Induced GliomasSemantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.Semantic proximity Read ↗

Accelerated progression of IDH mutant glioma after first recurrenceSemantic proximity Read ↗

Timing Matters: Overall Treatment Time, Radiotherapy Interruptions, and Outcomes in glioblastomas – Prognostic Significance in Different Biological Sub- GroupsSemantic proximity Read ↗

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).Semantic proximity Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

Assessment of Therapeutic Outcome and Role of Reirradiation in Patients With Radiation-induced GliomaSemantic proximity Read ↗

Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic FactorsSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.